Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.59
PGNX's Cash-to-Debt is ranked lower than
68% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PGNX: 2.59 )
Ranked among companies with meaningful Cash-to-Debt only.
PGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.59  Med: No Debt Max: No Debt
Current: 2.59
Equity-to-Asset 0.49
PGNX's Equity-to-Asset is ranked lower than
67% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
PGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.87 Max: 0.98
Current: 0.49
0.31
0.98
Interest Coverage 5.95
PGNX's Interest Coverage is ranked lower than
81% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: 5.95 )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: 5.95  Med: No Debt Max: No Debt
Current: 5.95
Piotroski F-Score: 6
Altman Z-Score: 0.61
Beneish M-Score: 0.50
WACC vs ROIC
24.83%
68.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 15.24
PGNX's Operating Margin % is ranked higher than
86% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. PGNX: 15.24 )
Ranked among companies with meaningful Operating Margin % only.
PGNX' s Operating Margin % Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 18.87
Current: 15.24
-878.82
18.87
Net Margin % 10.24
PGNX's Net Margin % is ranked higher than
86% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. PGNX: 10.24 )
Ranked among companies with meaningful Net Margin % only.
PGNX' s Net Margin % Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 15.56
Current: 10.24
-876.82
15.56
ROE % 7.77
PGNX's ROE % is ranked higher than
88% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PGNX: 7.77 )
Ranked among companies with meaningful ROE % only.
PGNX' s ROE % Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: 7.77
-87.75
16.86
ROA % 4.56
PGNX's ROA % is ranked higher than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PGNX: 4.56 )
Ranked among companies with meaningful ROA % only.
PGNX' s ROA % Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: 4.56
-79.08
14.53
ROC (Joel Greenblatt) % 272.88
PGNX's ROC (Joel Greenblatt) % is ranked higher than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PGNX: 272.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 365.68
Current: 272.88
-1585.16
365.68
3-Year Revenue Growth Rate 91.50
PGNX's 3-Year Revenue Growth Rate is ranked higher than
93% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. PGNX: 91.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -55.5  Med: -16.25 Max: 91.5
Current: 91.5
-55.5
91.5
GuruFocus has detected 2 Warning Signs with Progenics Pharmaceuticals Inc $PGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PGNX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PGNX Guru Trades in Q2 2016

Mario Gabelli 25,000 sh (New)
Ken Fisher 140,361 sh (+0.12%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (-0.93%)
Chuck Royce 1,913,350 sh (-10.52%)
» More
Q3 2016

PGNX Guru Trades in Q3 2016

Joel Greenblatt 48,873 sh (New)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 1,728,350 sh (-9.67%)
Ken Fisher 107,663 sh (-23.30%)
Mario Gabelli 17,000 sh (-32.00%)
Paul Tudor Jones 287,813 sh (-87.71%)
» More
Q4 2016

PGNX Guru Trades in Q4 2016

Joel Greenblatt 529,614 sh (+983.65%)
Murray Stahl 67,200 sh (unchged)
Mario Gabelli Sold Out
Chuck Royce 1,459,174 sh (-15.57%)
Ken Fisher 79,028 sh (-26.60%)
Paul Tudor Jones 4,200 sh (-98.54%)
» More
Q1 2017

PGNX Guru Trades in Q1 2017

Jim Simons 243,389 sh (New)
Paul Tudor Jones 10,100 sh (+140.48%)
Joel Greenblatt 676,791 sh (+27.79%)
Ken Fisher 97,632 sh (+23.54%)
Murray Stahl 67,260 sh (+0.09%)
Chuck Royce 1,250,674 sh (-14.29%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GERN, NAS:BOLD, OTCPK:SXMDF, NAS:ADAP, OTCPK:SNBIF, NAS:ACIU, NAS:IMGN, NAS:NTLA, NAS:ITCI, NAS:SPPI, NAS:MACK, NAS:INO, NAS:ATRA, NAS:SYRS, NAS:BCRX, NAS:CTMX, NAS:ANAB, NAS:CARA, NAS:NLNK, NAS:RETA » details
Traded in other countries:PGP.Germany,
Headquarter Location:USA
Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals is an American biotechnology company. The company develops innovative medicines to treat cancer. Progenics Pharmaceuticals' portfolio includes AZEDRA (to treat malignant and/or recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Top Ranked Articles about Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update
Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4
Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA®
- Novel, targeted radiotherapeutic for malignant and/or recurrent pheochromocytoma and paraganglioma –
- Study achieves primary endpoint -- Secondary endpoint shows favorable tumor response to therapy -- Company to submit NDA in mid-2017 --Conference call at 8:30 a.m. Eastern Time today -NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that the Company’s registrational Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® (iobenguane I 131) Injection, has achieved its primary endpoint. The open-label, multi-center study was conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). The trial was designed to evaluate the efficacy and safety of AZEDRA in patients with malignant and/or recurrent pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors. There are currently no approved therapeutics in the U.S. for the treatment of malignant and/or recurrent pheochromocytoma or paraganglioma. AZEDRA has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA.The study met the primary endpoint evaluating the proportion of patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months. Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.In the trial, 17 (25%) of the 68 evaluable patients experienced a 50% or greater reduction of all antihypertensive medication for at least 6 months.  The lower limit of the 95% confidence interval was 16.15%, thus meeting the primary endpoint.  The upper limit of the 95% confidence interval was 36.52%.Progenics also reported favorable data from a key secondary endpoint, the proportion of patients with overall tumor response as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.  In this highly pre-treated patient population, 92.2% of patients who received at least one AZEDRA therapeutic dose achieved partial response or stable disease.“The positive data from this trial are clinically meaningful and provide compelling evidence for the use of AZEDRA to treat malignant and/or recurrent pheochromocytoma and paraganglioma,” said Dr. Daniel Pryma, Associate Professor of Radiology & Radiation Oncology and Chief, Division of Nuclear Medicine & Clinical Molecular Imaging at the Perelman School of Medicine at the University of Pennsylvania, the trial’s lead investigator. “Without any approved therapeutics in the U.S. for these rare and devastating life-threatening tumors, patients face a poor prognosis and few options. The tumor response data, in particular for the patients that received two doses, along with the adverse event profile from this trial, suggest that AZEDRA has the potential to be a true breakthrough in addressing these difficult-to-treat patients.”Phase 2b Trial Topline Results
The Phase 2b open-label trial was designed to evaluate the efficacy and safety of two therapeutic doses of AZEDRA administered three months apart to patients with malignant relapsed/refractory pheochromocytoma or paraganglioma.Primary Endpoint: Reduction in Antihypertensive Medications
Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.  In order to achieve this primary endpoint, a minimum of 12 of the total 68 evaluable patients must have a 50% or greater reduction of all antihypertensive medication for at least 6 months.  As shown in the table below, 17 patients responded, giving a lower limit of the 95% confidence interval of 16.15%, thus meeting the primary endpoint. Responders (%)Lower bound of
Confidence IntervalUpper bound of
Confidence IntervalOverall
(n=68)17 (25%)

16.15

%

36.52

%

Two Doses
(n=50)16 (32%)

20.70

%

45.87

%

One Dose
(n=18)1 (5.6%)

0.0

%

27.65

%


Secondary Endpoint: Overall Tumor Response Assessment per RECIST Criteria
Best response over 12 months after first therapeutic dose Complete
ResponsePartial
ResponseStable Disease

Progressive
DiseaseUnable to
EvaluateOverall
(n=64*)0

%

23.4

%

68.8

%

4.7

%

3.1

%

2 doses
(n=50)0

%

30.0

%

68.0

%

2.0

%

0

%

1 dose
(n=14)0

%

0

%

71.4

%

14.3

%

14.3

%

*4 patients did not have follow-up scansAZEDRA was generally well tolerated. The most common treatment emergent adverse events were nausea, thrombocytopenia, anemia, fatigue, leukopenia, and neutropenia.  These events are consistent with those observed in prior AZEDRA studies.“We intend to move quickly to complete our New Drug Application submission by mid-2017, as these topline results underscore the potential of AZEDRA in this ultra-orphan indication,” said Mark Baker, Chief Executive Officer of Progenics. “We are grateful to the patients and investigators who participated in this trial, and are committed to bringing a new treatment option to this rare cancer population.”Progenics plans to present additional data from this trial at a medical meeting in the second half of 2017.Conference Call and Webcast
Progenics will further review these topline results from the registrational Phase 2b trial of AZEDRA® in a conference call today at 8:30 a.m. ET. To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 99400682. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks.About AZEDRA®AZEDRA® (iobenguane I 131) Injection, a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. AZEDRA has been granted Breakthrough Therapy and Orphan Drug designations, as well as Fast Track status in the U.S. Under a SPA agreement with the U.S. Food and Drug Administration (FDA), a Phase 2 registrational study has been completed in patients with malignant and/or recurrent pheochromocytoma and paraganglioma.  There are currently no FDA-approved therapies for the treatment of these ultra-orphan diseases.About Pheochromocytoma and ParagangliomaPheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas are located outside the adrenal glands, they are called paragangliomas. Standard treatment options for these tumors include surgery, palliative therapy and symptom management. Pheochromocytoma and paraganglioma tumors frequently secrete high levels of hormones that can lead to life threatening hypertension, heart failure, and stroke in these patients.  Malignant and recurrent pheochromocytoma and paraganglioma may result in unresectable disease with a poor prognosis, representing a significant management challenge with very limited treatment options and no approved anti-tumor therapies.About ProgenicsProgenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings.(PGNX-F)
Contact:

Melissa Downs
Investor Relations
(646) 975-2533
[email protected]

Read more...
Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, will present at the 16th Annual Needham Healthcare Conference in New York City on Wednesday, April 5, 2017 at 10:00 a.m. Eastern Time.
A live webcast of the Needham presentation will be available in the Media Center of the Progenics website, www.progenics.com. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archive of the event will be available for 90 days. About Progenics Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc. This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings. (PGNX-F)  

Contact:         
Melissa Downs
Investor Relations
(914) 789-2801
[email protected]

Read more...
Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine
NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the publication of previously-reported results from the Phase 2 study of 1404 in the online edition of the Journal of Nuclear Medicine.  1404 is a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer.
The data published today reviews previously reported data demonstrating the sensitivity of 1404 to detect prostate cancer using both visual and semi-quantitative tumor to background (TBR) scores.  The uptake within the prostate gland evaluated by both visual and TBR scores correlated significantly with Gleason Score.“The results from this study highlight the potential for 1404 to better assess the stage and extent of a patient’s prostate cancer versus biopsy,” stated Professor Karolien Goffin, M.D., Ph.D., University Hospitals Leuven, author of the publication. “Importantly, 1404 may be used as a surrogate marker for Gleason Score, and could be used to evaluate lymph node involvement in patients with intermediate and high risk prostate cancer, which signals disease that has spread beyond the prostate.  The data provide a strong rationale for continued development of 1404.”Progenics is currently evaluating 1404 in a Phase 3 study.  The study is enrolling patients with newly diagnosed low grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ≤ 3 4 severity and/or are candidates for active surveillance. The study is designed to evaluate the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.About 1404, an Imaging Compound Targeting Prostate Specific Membrane AntigenProgenics' molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of > 95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with Technetium-99m, a gamma-emitting isotope that is widely available, is easy to prepare, and is attractive for nuclear medicine imaging applications. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.
About Prostate CancerProstate cancer is the second most common form of cancer affecting men in the United States: an estimated one in seven men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that each year approximately 161,360 new cases of prostate cancer will be diagnosed and about 26,730 men will die of the disease. Approximately 2.9 million men in the U.S. currently count themselves among prostate cancer survivors.About ProgenicsProgenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company's pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company's SEC filings.(PGNX-F)
Contact:

Melissa Downs
Investor Relations
(646) 975-2533
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 69.50
PGNX's PE Ratio is ranked lower than
75% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. PGNX: 69.50 )
Ranked among companies with meaningful PE Ratio only.
PGNX' s PE Ratio Range Over the Past 10 Years
Min: 12.75  Med: 76.71 Max: 925
Current: 69.5
12.75
925
PE Ratio without NRI 69.50
PGNX's PE Ratio without NRI is ranked lower than
75% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. PGNX: 69.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
PGNX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.75  Med: 76.71 Max: 925
Current: 69.5
12.75
925
Price-to-Owner-Earnings 42.38
PGNX's Price-to-Owner-Earnings is ranked lower than
51% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. PGNX: 42.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PGNX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.12  Med: 36.95 Max: 144.53
Current: 42.38
22.12
144.53
PB Ratio 5.47
PGNX's PB Ratio is ranked lower than
71% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PGNX: 5.47 )
Ranked among companies with meaningful PB Ratio only.
PGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.53 Max: 9.03
Current: 5.47
1.08
9.03
PS Ratio 7.05
PGNX's PS Ratio is ranked higher than
56% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. PGNX: 7.05 )
Ranked among companies with meaningful PS Ratio only.
PGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.91  Med: 8.59 Max: 177.27
Current: 7.05
1.91
177.27
Price-to-Free-Cash-Flow 46.32
PGNX's Price-to-Free-Cash-Flow is ranked lower than
66% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. PGNX: 46.32 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PGNX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.91  Med: 35.64 Max: 458.82
Current: 46.32
10.91
458.82
Price-to-Operating-Cash-Flow 34.06
PGNX's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. PGNX: 34.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PGNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.75  Med: 32.05 Max: 278.57
Current: 34.06
10.75
278.57
EV-to-EBIT 38.84
PGNX's EV-to-EBIT is ranked lower than
78% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PGNX: 38.84 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.8  Med: -2.7 Max: 301.4
Current: 38.84
-50.8
301.4
EV-to-EBITDA 33.80
PGNX's EV-to-EBITDA is ranked lower than
76% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PGNX: 33.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
PGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.8  Med: -3 Max: 233.2
Current: 33.8
-132.8
233.2
Current Ratio 9.20
PGNX's Current Ratio is ranked higher than
75% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PGNX: 9.20 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.11 Max: 32.92
Current: 9.2
2.67
32.92
Quick Ratio 9.20
PGNX's Quick Ratio is ranked higher than
76% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PGNX: 9.20 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.11 Max: 32.92
Current: 9.2
2.67
32.92
Days Sales Outstanding 11.04
PGNX's Days Sales Outstanding is ranked higher than
80% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. PGNX: 11.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 40.83 Max: 180.24
Current: 11.04
0.36
180.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
PGNX's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PGNX: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.6  Med: -11.25 Max: -2.1
Current: -4.9
-73.6
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.79
PGNX's Price-to-Net-Cash is ranked lower than
76% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. PGNX: 14.79 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 6.52 Max: 22.41
Current: 14.79
0
22.41
Price-to-Net-Current-Asset-Value 12.64
PGNX's Price-to-Net-Current-Asset-Value is ranked lower than
74% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PGNX: 12.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 5.95 Max: 18.68
Current: 12.64
0
18.68
Price-to-Tangible-Book 10.69
PGNX's Price-to-Tangible-Book is ranked lower than
81% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PGNX: 10.69 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22  Med: 5.18 Max: 13.49
Current: 10.69
1.22
13.49
Price-to-Median-PS-Value 0.82
PGNX's Price-to-Median-PS-Value is ranked lower than
57% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PGNX: 0.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.42 Max: 15.05
Current: 0.82
0
15.05
Price-to-Graham-Number 5.74
PGNX's Price-to-Graham-Number is ranked lower than
77% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. PGNX: 5.74 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PGNX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 4.2 Max: 15.87
Current: 5.74
0
15.87
Earnings Yield (Greenblatt) % 2.56
PGNX's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PGNX: 2.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 2.2 Max: 10.2
Current: 2.56
0.3
10.2

More Statistics

Revenue (TTM) (Mil) $69.33
EPS (TTM) $ 0.10
Beta3.96
Short Percentage of Float19.78%
52-Week Range $4.00 - 11.72
Shares Outstanding (Mil)70.23

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) 0.55
EPS without NRI ($) 0.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update May 04 2017 
Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4 Apr 27 2017 
Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology Apr 20 2017 
Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of A Mar 30 2017 
Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference Mar 30 2017 
Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Mar 24 2017 
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 

More From Other Websites
Today's Research Reports on Biotech Stocks to Watch: Novavax and Progenics Pharmaceuticals May 19 2017
Edited Transcript of PGNX earnings conference call or presentation 4-May-17 12:30pm GMT May 12 2017
PetMed (PETS) Beats Earnings, Revenue Estimates in Q4 May 09 2017
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View May 09 2017
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View May 09 2017
Phibro (PAHC) Posts In Line Earnings in Q3, Revises View May 09 2017
Align Technology Invisalign Sales Strong, Currency Woes Stay May 08 2017
Qiagen Banks on Molecular Diagnostic amid Currency Woes May 08 2017
CVS Down on Weak Earnings, Pharmacy Services Remains Strong May 08 2017
VWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure May 08 2017
BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss May 05 2017
Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag May 05 2017
Progenics reports 1Q loss May 04 2017
Cardiovascular Systems (CSII) Swings to Earnings in Q3 May 04 2017
Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates May 04 2017
Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update May 04 2017
Investor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call May 04 2017
AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y May 03 2017
Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View May 03 2017
Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2 May 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat